Thank you, Julissa. 2025 was a truly transformative year for Verastem as we transition to a commercial stage company following our FDA approval of the first treatment specifically for KRAS-mutated ...

Q4 2025 Earnings Call March 3, 2026 4:30 PM ESTCompany ParticipantsPatrick Soon-Shiong - Founder, Executive Chairman and ...

This Rule Breaker Investing Mailbag picks up where Pet Peeves left off. Listeners wrote in with their own linguistic ...